Stoke Therapeutics Inc

Stoke Therapeutics stock dips 16.9% from its peak as investors weigh its high P/E, biotech innovation and talent‑retention grants, prompting a cautious analysis of its $1.83B market cap and future prospects.

Stoke Therapeutics Inc. is poised for growth as it prepares to release its Q2 2025 earnings report, with promising developments in its clinical pipeline and a potential game-changing treatment for Dravet syndrome on the horizon.

Stoke Therapeutics Inc’s stock has experienced significant fluctuations, raising concerns about the company’s ability to deliver on its promises and achieve long-term success despite its groundbreaking approach to treating diseases.